nemonapride

Nemonapride is a benzamide-derivative atypical antipsychotic used orally for the treatment of schizophrenia, primarily approved in Japan and China. Its main mechanism is antagonism of dopamine D2, D3, and D4 receptors, and it acts as a partial agonist at the serotonin 5-HT1A receptor. Developed initially by Yamanouchi Pharmaceuticals (now part of Astellas Pharma), it is structurally related to sulpiride and other benzamide antipsychotics. While effective for positive symptoms of schizophrenia, it is associated with typical side effects like akathisia, dystonia, hypokinesia, tremor, hypersalivation, and hyperprolactinemia, but comparatively exhibits a lower risk of extrapyramidal symptoms than many typical antipsychotics. Its clinical data are somewhat limited, and the drug is not approved outside Japan and China[1][4][7].

Brand names

EmilaceEmirace

Other names

emonapride(+/-)-cis-n-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamideN-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide